Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Genitourinary Cancer

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Eur Urol.

Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW

doi: 10.1016/j.eururo.2017.02.023.

Gastrointestinal CancerSkin Cancer

Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy

Cancer Biol Ther.

Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS

doi: 10.1080/

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Genitourinary Cancer

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY

doi: 10.1038/pcan.2016.58.

Genitourinary Cancer

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

J Immunother Cancer.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, Baciarello G, Loriot Y, Fizazi K

doi: 10.1186/s40425-017-0232-7.

Genitourinary Cancer

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Genitourinary Cancer

A Novel Patient Case Report to Show the Successful Termination of Untreatable Androgen-independent Prostate Cancer: Treatment with Cabergoline (Dopamine agonist)

Mathews J Case Rep.

Costello LC, Franklin RB, Yu GW

Immunotherapy in Gastrointestinal Cancers

Biomed Res Int.

Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S

doi: 10.1155/2017/4346576.

Gynecologic Cancer

Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer

J Immunother.

Oh MS, Chae YK

doi: 10.1097/CJI.

Related content

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

A Novel Patient Case Report to Show the Successful Termination of Untreatable Androgen-independent Prostate Cancer: Treatment with Cabergoline (Dopamine agonist)

Immunotherapy in Gastrointestinal Cancers

Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer